Labderm Essence Sp. z o.o. — Clinical Trial Site

18 Registered trials

5 Currently recruiting

Organisation

Labderm Essence Sp. z o.o.

Location

Ozarowice, Poland

Identifier

ORG-100047745

Address

Ul. Lesna 2a, Ossy, 42-624, Poland

Departments

#5706:Dermatology
0503: dermatology
1704: Dermatology
2692
501: Dermatology
Dermatology
Labderm s.c., Beata Bergler-Czop, Barbara Sido-Bergler
N/A
NA
Niepubliczny Zakład Opieki Zdrowotnej Labderm S.C.

Clinical trials at this site (18)

Search interface

A Long-Term Extension Study to Evaluate the Safety and Efficacy of Ritlecitinib in Participants With Severe AA Who Have Completed Studies B7… Pending

2024-515439-31-00 Alopecia areata 5
Phase 2 Proof-of-Concept Study of LAD328 in Adults with Hidradenitis Suppurativa Recruiting

2025-521865-29-00 moderate-to-severe hidradenitis suppurativa 4 2026-04-30
A first-in-human, open-label, dose finding study to evaluate the safety, tolerability and pharmacokinetics of EGL-003 in healthy volunteers … Recruiting

2025-521658-40-00 Atopic dermatitis 1 2025-10-27
A study to assess NAV-240 in adult participants with Hidradenitis Suppurativa Recruiting

2025-523557-33-00 Moderate-to-Severe Hidradenitis Suppurativa 4 2026-04-20
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hid… Recruiting

2025-520564-17-00 Hidradenitis suppurativa (HS) 5 2025-10-16
Extension study to assess effects of non-interrupted versus interrupted and long term treatment of two dose regimens on efficacy and safety … Recruiting

2023-508956-20-00 Hidradenitis suppurativa 5 2020-03-12
A Phase 3 Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 Years of Age With Severe Alopecia Areata Ended

2024-515438-33-00 Alopecia areata 5 2026-01-12
A Clinical Study in which patients with acne vulgaris will receive a new topical drug. The safety and efficacy of the drug will be tested. Ended

2023-510339-12-00 acne vulgaris 5 2024-11-11
A Clinical Study in which patients with acne vulgaris will receive a new topical drug for long term. The safety and efficacy of the drug wil… Ended

2023-510342-24-00 Acne vulgaris 5 2024-11-11
A Phase III study to investigate the efficacy and safety of anifrolumab in adults with chronic and/or subacute cutaneous lupus erythematosus Ended

2023-503692-24-00 Cutaneous Lupus Erythematosus 5 2024-09-25
Open-label basket study for safety and pharmacokinetics evaluation of INF904 in subjects with CSU or HS Ended

2024-515615-22-00 Moderate to Severe Chronic Spontaneous Urticaria (CSU) 4 2025-04-02
Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients with… Ended

2024-514562-40-00 Hidradenitis suppurativa (HS) 4 2025-03-13
A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe … Ended

2024-511360-87-00 hidradenitis suppurativa (HS) 5 2024-10-02
A Phase 2 study to evaluate the efficacy and safety of SAR444656 compared with placebo in adult participants with moderate to severe hidrade… Ended

2023-504328-25-00 hidradenitis suppurativa 4 2023-12-27
A Phase 3, Multicentre, Randomised, Double-blind, Vehicle-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tirbanibul… Ended

2023-505487-11-00 Actinic Keratosis on the Face or Scalp 5 2023-12-21
Hidradenitis Suppurativa Phase 3 Study of Izokibep Ended

2022-503160-33-00 Hidradenitis Suppurativa 5 2023-12-15
BP11 Versus EU-Approved Xolair® in Patients With Chronic Spontaneous Urticaria Ended

2024-514764-72-00 Chronic Urticaria 5 2023-09-27
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid Ended

2024-510745-34-00 Bullous Pemphigoid 10 2020-11-11